| Market Overview
The global hematology
analyzers market size reached USD 7.3 Billion in 2024. It is expected to
grow to USD 13.4 Billion by 2033, exhibiting a CAGR of 7.01% during the
forecast period 2025-2033. Market growth is driven primarily by rising
prevalence of blood disorders, technological advancements, and increasing
laboratory automation to meet demand for accurate diagnostics.
Study Assumption Years
• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033
Hematology Analyzers Market Key Takeaways
• Market Size in 2024: USD 7.3 Billion
• CAGR: 7.01% during 2025-2033
• Forecast Period: 2025-2033
• The market is primarily driven by increasing prevalence of blood disorders
like anemia, leukemia, lymphoma, myeloma, hemophilia, and von Willebrand
disease.
• Increasing adoption of automated hematology tests and advances in technology
contribute significantly to market growth.
• North America leads the market due to advanced healthcare infrastructure and
rising adoption of innovative technologies.
• Asia-Pacific shows rapid growth owing to increasing healthcare expenditure
and awareness.
• Challenges include rising instrument costs and shortage of skilled
professionals.
Sample Request Link: https://www.imarcgroup.com/hematology-analyzers-market/requestsample
Market Growth Factors
The increase of the prevalence of blood disorders like anemia, leukemia,
lymphoma, myeloma, hemophilia, and von Willebrand disease is also expected to
fuel market growth. These hematology analyzers can inform about blood cells in
detail, which enables doctors to diagnose early, treat disease, and monitor
blood-related disorders. This increase in incidence is directly increasing
demand across healthcare.
The market is growing due to the high demand for hematology
analyzers, the rapid technological growth of hematology analyzers, and the
growth in the automation of hematology analyzers that provide high-throughput
screening and process a high number of blood samples quickly. The incorporation
of advanced software and artificial intelligence improved data analysis and the
early identification of patterns of hematological disease that improve
effective treatment.
High-throughput hematology analyzers with high reliability,
accuracy, flexibility, and ease of use, increased blood donations, increased
incidences of blood disorders, and introduction of advanced diagnostic products
and reagents are expected to drive growth of sanguineous diagnostics market
during the forecast period. The global uptake of the products for patient
assessment also increased during the COVID-19 pandemic.
Market Segmentation
• Product Type: 3 Parts, 5 Parts, Point of Care Testing, Others
3 parts account for the majority market share, being more affordable and
simpler to operate, suitable for small to medium healthcare facilities with
limited budgets and expertise. Manufacturers like Sysmex Corporation are
investing in advanced variants such as XR-Series and XQ-Series models.
• Type: Fully Automated Analyzers, Semi-automated
Analyzers
The report provides detailed segmentation without specific dominant segment
data.
• Price Range: High-end Analyzers, Mid-range
Analyzers, Low-end Analyzers
Low-end analyzers represent the largest segment due to affordability and ease
of use, widely adopted in small labs, clinics, and hospitals, especially in
developing regions. Rising incidence of hematological malignancies also drives
adoption.
• End-User: Hospitals, Clinical Laboratories,
Research Institutes, Others
Hospitals exhibit a clear dominance due to high patient volume and need for
accurate and rapid blood analysis, supported by digital transformation and
adoption of electronic health record systems.
Regional Insights
North America leads the hematology analyzers market, accounting for the
largest market share. The region benefits from advanced healthcare
infrastructure, widespread access to diagnostics, and high per capita
healthcare spending. For instance, the U.S. National Health Expenditure grew
4.1% to US$4.5 Trillion in 2022, which represents US$13,493 per person and
17.3% of GDP. Asia-Pacific is rapidly growing owing to increasing healthcare
expenditure and awareness among the population.
Recent Developments & News
In May 2022, Nihon Kohden India established a new hematology analyzer
reagent factory expected to be operational by Spring 2024 to meet rising
reagent demand alongside the expanding hematology instrument base. In May 2023,
Siemens Healthineers introduced two high-volume hematology test systems,
Atellica Hema 570 Analyzer and Atellica Hema 580 Analyzer, unveiled at
EuroMedLab 2023, designed for integrated automation and intelligence to enhance
workflow efficiency and accelerate testing results.
Key Players
• Abbott Diagnostics
• Roche Diagnostics
• Danaher Corporation
• Diatron
• Drew Scientific
• Siemens Healthineers
• Sysmex Corporation
• Bio-Rad Laboratories
• Horiba
• Vital Diagnostics
If you require any specific information that is not
covered currently within the scope of the report, we will provide the same as a
part of the customization.
Request for Customization: https://www.imarcgroup.com/request?type=report&id=22339&flag=E
About Us
IMARC Group is a global management consulting firm that helps the world’s
most ambitious changemakers to create a lasting impact. The company provide a
comprehensive suite of market entry and expansion services. IMARC offerings
include thorough market assessment, feasibility studies, company incorporation
assistance, factory setup support, regulatory approvals and licensing
navigation, branding, marketing and sales strategies, competitive landscape and
benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302 | 